Innovation payment schemes

In September 2024, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced two projects that received a subsidy under the "Subsidy scheme for promising care" in 2024 for research on the cost-effectiveness of cold plasma therapy for diabetic foot or venous leg wounds and intranasal mesenchymal stem cells in newborns with hypoxic-ischemic brain damage.

On September 2, 2024, the French Ministry of Health released further details on the renewed support for innovation in medical biology and anatomopathology procedures via the Repository of Innovative Services outside the Nomenclature of biology and anatomopathology (RIHN) 2.0 including criteria for application.

In mid-August 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for another four completed projects. The projects were dedicated to the topics of support for families with a parent suffering from cancer, modeling routine risk screening in children, reducing problematic media use, promoting treatment motivation in people with computer game addiction and Internet addiction, and follow-up care for gestational diabetes.

In late June – mid-July 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for another three completed projects. The projects were dedicated to the topics of care concept for patients with hidradenitis suppurativa (acne inversa), the use of webcams in neonatal intensive care units, and improving the pharmacovigilance of innovative therapies.

On May 27, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) announced that ninety-one applications (project ideas) for innovation funding of the projects for new forms of care were received.

On May 17, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for another three completed projects. The projects were dedicated to the topics of booster vaccination against meningococci of serogroup C, reduction of antibiotic resistance, and dual pilot structure for diagnosis clarification in centers for rare diseases.

On May 17, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) announced that forty-eight applications for innovation funding of healthcare research projects were accepted.

On April 22, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) announced that fourteen applications for innovation funding of development or further development of the clinical guidelines were accepted.

On April 19, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) announced the start of the application period for submission of the proposed topics for new funding announcements for the projects in the field of health services research, as well as for the new forms of care.

On March 31, 2024, the Ministry of Labor, Health, and Solidarity published a Decree in the Official Journal of the French Republic relating to the conditions of coverage of innovative IVD tests within the RIHN framework, which should facilitate the transition from the RIHN framework to regular reimbursement via the NABM Nomenclature.

In April 2024, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced two projects which received a subsidy under the "Subsidy scheme for promising care" in 2024 for research of targeted muscle reinnervation during leg amputation and thrombectomy by catheterization in adult patients with a high-risk pulmonary embolism.

On November 14, 2023, the Institute for the Hospital Remuneration System (InEK) published the DRG catalog (Fallpauschalen-Katalog) with the list of DRGs and additional reimbursement categories (ZEs) for 2024.